Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials

Author:

Fischinger StephanieORCID,Cizmeci DenizORCID,Deng DavyORCID,Grant Shannon P.,Frahm NicoleORCID,McElrath JulieORCID,Fuchs JonathanORCID,Bart Pierre-AlexandreORCID,Pantaleo Giuseppe,Keefer Michael,O. Hahn William,Rouphael Nadine,Churchyard Gavin,Moodie ZoeORCID,Donastorg Yeycy,Streeck HendrikORCID,Alter GalitORCID

Abstract

Despite the advent of long-acting anti-retroviral therapy able to control and prevent infection, a preventative vaccine remains a global priority for the elimination of HIV. The moderately protective RV144 vaccine trial suggested functional IgG1 and IgG3 antibodies were a potential correlate of protection, but the RV144-inspired HVTN702 validation trial failed to demonstrate efficacy despite inducing targeted levels of IgG1/IgG3. Alterations in inserts, and antigens, adjuvant, and regimen also resulted in vaccine induced target quantitative levels of the immune correlates, but drove qualitative changes to the humoral immune response, pointing to the urgent need to define the influence of vaccine strategies on shaping antibody quality, not just quantity. Thus, defining how distinct prime/boost approaches tune long-lived functional antibodies represents an important goal in vaccine development. Here, we compared vaccine responses in Phase I and II studies in humans utilizing various combinations of DNA/vector, vector/vector and DNA/protein HIV vaccines. We found that adenoviral vector immunization, compared to pox-viral vectors, resulted in the most potent IgG1 and IgG3 responses, linked to highly functional antibody activity, including assisting NK cell related functions. Minimal differences were observed in the durability of the functional humoral immune response across vaccine regimens, except for antibody dependent phagocytic function, which persisted for longer periods in the DNA/rAd5 and rAd35/rAd5 regimen, likely driven by higher IgG1 levels. Collectively, these findings suggest adenoviral vectors drive superior antibody quality and durability that could inform future clinical vaccine studies. Trial registration: ClinicalTrials.gov NCT00801697, NCT00961883, NCT02207920, NCT00125970, NCT02852005).

Funder

National Institutes of Health

Ragon Institute Sundry

SAMANA Kay MGH Research Scholar Program

Gates Foundation

MGH ECOR Scholars Program

Publisher

Public Library of Science (PLoS)

Subject

Virology,Genetics,Molecular Biology,Immunology,Microbiology,Parasitology

Reference53 articles.

1. Antiretroviral Therapy for the Prevention of HIV-1 Transmission;MS Cohen;N Engl J Med,2016

2. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations;VA Fonner;AIDS,2016

3. UNAIDS. 2017 Global HIV Statistics. Fact sheet. 2018.

4. The Quest for an HIV-1 Vaccine—Moving Forward;DH Barouch;N Engl J Med,2013

5. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand;S Rerks-Ngarm;N Engl J Med,2009

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Viral vector vaccines;Current Opinion in Immunology;2022-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3